Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLUTION: Vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia
2021-000350-26Phase 2Active
- Sponsor
- Oryzon Genomics
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Vafidemstat with Placebo (2 arms). Primary endpoint: Change from baseline to week 24 in PANSS Factor Score for Negative Symptoms. Started Jul 2021; status: active.
02
Drugs
vafidemstat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2021-000350-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000350-26.